Search research articles
Contact Us
Filters
Showing results (1-10 of 26) with videos related to
Page
of 3
Sort By:
Immunotherapy
|
December 14, 2011
Conference scene: Recent advancements in immunotherapy
Palak Trivedi
Current Opinion in Pharmacology
|
December 11, 2021
Emerging drugs for the treatment of primary sclerosing cholangitis
Nadir Abbas, Mohammad Nabil Quraishi, Palak Trivedi
World Journal of Gastroenterology
|
March 18, 2009
Intraductal papillary mucinous neoplasm in chronic calcifying pancreatitis: egg or hen?
Evangelos Kalaitzakis, Barbara Braden, Palak Trivedi, et al.
British Journal of Hospital Medicine (London, England : 2005)
|
October 8, 2019
Challenges in the use of corticosteroids in the management of autoimmune hepatitis
Roger W Chapman, Richard J Aspinall, Palak Trivedi, et al.
JHEP Reports : Innovation in Hepatology
|
July 9, 2024
Erratum to "Opinion paper on the diagnosis and treatment of progressive familial intrahepatic cholestasis" [JHEP Reports 6 (2024) 100949]
Patrick McKiernan, Jesus Quintero Bernabeu, Muriel Girard, et al.
Alimentary Pharmacology & Therapeutics
|
March 30, 2026
Review Article: Targeting Peroxisome Proliferator-Activated Receptors in Primary Biliary Cholangitis
Jörn M Schattenberg, Jesus M Banales, Gideon Hirschfield, et al.
BMJ Open Gastroenterology
|
March 3, 2025
Assessing brodalumab in the treatment of primary sclerosing cholangitis (SABR-PSC pilot study): protocol for a single-arm, multicentre, pilot study
Amera Elzubeir, Juliet High, Matthew Hammond, et al.
BMJ Open Gastroenterology
|
December 11, 2025
Pruritus and health-related quality of life in chronic liver disease: a longitudinal, survey-based cohort study
Usha Gungabissoon, Jake Hunnicutt, Eleanor J McDermott, et al.
Hepatology (Baltimore, Md.)
|
December 5, 2025
Pruritus is common in primary sclerosing cholangitis, persists over time, and its intensity is associated with disease severity
Nasir Hussain, Rodrigo V Motta, Usha Gungabissoon, et al.
BMC Gastroenterology
|
March 16, 2023
PRIMIS: design of a pivotal, randomized, phase 3 study evaluating the safety and efficacy of the nonsteroidal farnesoid X receptor agonist cilofexor in noncirrhotic patients with primary sclerosing cholangitis
Michael Trauner, Chuhan Chung, Kate Sterling, et al.
Page
of 3
Search research articles
Search
Showing results (1-10 of 26) with videos related to
Sort By:
Page
of 3
Immunotherapy
|
December 14, 2011
Conference scene: Recent advancements in immunotherapy
Palak Trivedi
Current Opinion in Pharmacology
|
December 11, 2021
Emerging drugs for the treatment of primary sclerosing cholangitis
Nadir Abbas, Mohammad Nabil Quraishi, Palak Trivedi
World Journal of Gastroenterology
|
March 18, 2009
Intraductal papillary mucinous neoplasm in chronic calcifying pancreatitis: egg or hen?
Evangelos Kalaitzakis, Barbara Braden, Palak Trivedi, et al.
British Journal of Hospital Medicine (London, England : 2005)
|
October 8, 2019
Challenges in the use of corticosteroids in the management of autoimmune hepatitis
Roger W Chapman, Richard J Aspinall, Palak Trivedi, et al.
JHEP Reports : Innovation in Hepatology
|
July 9, 2024
Erratum to "Opinion paper on the diagnosis and treatment of progressive familial intrahepatic cholestasis" [JHEP Reports 6 (2024) 100949]
Patrick McKiernan, Jesus Quintero Bernabeu, Muriel Girard, et al.
Alimentary Pharmacology & Therapeutics
|
March 30, 2026
Review Article: Targeting Peroxisome Proliferator-Activated Receptors in Primary Biliary Cholangitis
Jörn M Schattenberg, Jesus M Banales, Gideon Hirschfield, et al.
BMJ Open Gastroenterology
|
March 3, 2025
Assessing brodalumab in the treatment of primary sclerosing cholangitis (SABR-PSC pilot study): protocol for a single-arm, multicentre, pilot study
Amera Elzubeir, Juliet High, Matthew Hammond, et al.
BMJ Open Gastroenterology
|
December 11, 2025
Pruritus and health-related quality of life in chronic liver disease: a longitudinal, survey-based cohort study
Usha Gungabissoon, Jake Hunnicutt, Eleanor J McDermott, et al.
Hepatology (Baltimore, Md.)
|
December 5, 2025
Pruritus is common in primary sclerosing cholangitis, persists over time, and its intensity is associated with disease severity
Nasir Hussain, Rodrigo V Motta, Usha Gungabissoon, et al.
BMC Gastroenterology
|
March 16, 2023
PRIMIS: design of a pivotal, randomized, phase 3 study evaluating the safety and efficacy of the nonsteroidal farnesoid X receptor agonist cilofexor in noncirrhotic patients with primary sclerosing cholangitis
Michael Trauner, Chuhan Chung, Kate Sterling, et al.
Page
of 3